Transitional cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:54:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Transitional cell carcinoma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Futibatinib and Pembrolizumab for Patients with Advanced or Metastatic Bladder, Urethra, or Pelvis Cancer Not Suitable for Platinum Treatment https://clinicaltrials.eu/trial/study-of-futibatinib-and-pembrolizumab-for-patients-with-advanced-or-metastatic-bladder-urethra-or-pelvis-cancer-not-suitable-for-platinum-treatment/ Wed, 29 Apr 2026 14:27:18 +0000 https://clinicaltrials.eu/trial/study-of-futibatinib-and-pembrolizumab-for-patients-with-advanced-or-metastatic-bladder-urethra-or-pelvis-cancer-not-suitable-for-platinum-treatment/ This clinical trial is focused on studying the treatment of Advanced or Metastatic Urothelial Carcinoma, which is a type of cancer that affects the bladder, urethra, or pelvis. The study involves two medications: Futibatinib and Pembrolizumab. Futibatinib, also known by its code name TAS-120, is taken as a film-coated tablet, while Pembrolizumab, sometimes referred to by its code name MK-3475, is administered as a solution for infusion. The purpose of the study is to evaluate how well these medications work together in treating this type of cancer.

Participants in the study will receive both medications over a period of time. The study will monitor the response of the cancer to the treatment, looking for signs of improvement such as a reduction in tumor size or slowing of disease progression. The study will also assess the safety and tolerability of the treatment, keeping track of any side effects experienced by participants. The goal is to determine the effectiveness of the combination of Futibatinib and Pembrolizumab in patients who are not suitable for traditional platinum-based chemotherapy treatments.

Throughout the study, participants will have regular check-ups and assessments to monitor their health and the progress of the treatment. The study aims to provide valuable information on the potential benefits of using these medications together for treating Advanced or Metastatic Urothelial Carcinoma, offering hope for improved outcomes in patients with this challenging condition.

]]>